JP2019501927A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501927A5 JP2019501927A5 JP2018536252A JP2018536252A JP2019501927A5 JP 2019501927 A5 JP2019501927 A5 JP 2019501927A5 JP 2018536252 A JP2018536252 A JP 2018536252A JP 2018536252 A JP2018536252 A JP 2018536252A JP 2019501927 A5 JP2019501927 A5 JP 2019501927A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrate
- pharmaceutically acceptable
- acceptable salt
- cycloalkyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 4
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 4
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 4
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 4
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 2
- 206010012434 Dermatitis allergic Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662278085P | 2016-01-13 | 2016-01-13 | |
| US62/278,085 | 2016-01-13 | ||
| PCT/US2017/013100 WO2017123695A1 (en) | 2016-01-13 | 2017-01-12 | Isoquinolones as btk inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501927A JP2019501927A (ja) | 2019-01-24 |
| JP2019501927A5 true JP2019501927A5 (enExample) | 2020-02-13 |
| JP6916185B2 JP6916185B2 (ja) | 2021-08-11 |
Family
ID=57907002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018536252A Active JP6916185B2 (ja) | 2016-01-13 | 2017-01-12 | Ｂｔｋ阻害剤としてのイソキノロン類 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10570118B2 (enExample) |
| EP (1) | EP3402789B1 (enExample) |
| JP (1) | JP6916185B2 (enExample) |
| WO (1) | WO2017123695A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6959252B2 (ja) * | 2016-03-24 | 2021-11-02 | ミッション セラピューティクス リミティド | Ｄｕｂ阻害剤としての１−シアノピロリジン誘導体 |
| MA47106A (fr) | 2016-12-21 | 2019-10-30 | Amgen Inc | Formulations d'anticorps anti-tnf alpha |
| AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| WO2020234103A1 (en) * | 2019-05-21 | 2020-11-26 | Bayer Aktiengesellschaft | Identification and use of kras inhibitors |
| SI3972603T1 (sl) * | 2019-05-23 | 2025-02-28 | Novartis Ag | Postopki zdravljenja sjogrenovega sindroma z uporabo zaviralca brutonove tirozin kinaze |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| CN115650851A (zh) * | 2022-11-10 | 2023-01-31 | 无锡双启科技有限公司 | 一种2-氟-4-溴-6-甲基苯甲酸甲酯的制备方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9608435D0 (en) | 1996-04-24 | 1996-06-26 | Celltech Therapeutics Ltd | Chemical compounds |
| HRP20040098B1 (en) | 2001-08-13 | 2012-08-31 | Janssen Pharmaceutica N.V. | 2,4,5-TRlSUBSTITUTED THIAZOLYL DERIVATIVES AND THEIR ANTIINFLAMMATORY ACTIVITY |
| US7307097B2 (en) | 2001-09-27 | 2007-12-11 | Smithkline Beechman Corporation | Chemical compounds |
| FR2881426B1 (fr) | 2005-02-03 | 2007-03-30 | Aventis Pharma Sa | Pyrolles et imidazoles substitues, compositions les contenant, procede de frabrication et utilisation |
| AU2007235237B2 (en) | 2006-04-11 | 2011-08-18 | Vertex Pharmaceuticals Incorporated | Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases |
| SG166093A1 (en) | 2006-09-22 | 2010-11-29 | Pharmacyclics Inc | Inhibitors of brutonæs tyrosine kinase |
| CN101674834B (zh) | 2007-03-28 | 2013-06-12 | 环状药物公司 | 布鲁顿氏酪氨酸激酶(Bruton's tyrosine kinase)抑制剂 |
| WO2009098144A1 (en) * | 2008-02-05 | 2009-08-13 | F. Hoffmann-La Roche Ag | Novel pyridinones and pyridazinones |
| UA103327C2 (en) * | 2008-06-24 | 2013-10-10 | Ф. Хоффманн-Ля Рош Аг | Substituted pyridin-2-ones and pyridazin-3-ones |
| PL2310528T3 (pl) | 2008-07-29 | 2014-04-30 | Univ Liege | Marker genetyczny do testowania brachyspiny i płodności u bydła |
| GB0820819D0 (en) | 2008-11-13 | 2008-12-24 | Sareum Ltd | Pharmaceutical compounds |
| EP2391619A1 (en) | 2009-01-30 | 2011-12-07 | Millennium Pharmaceuticals, Inc. | Heteroaryls and their use as pi3k inhibitors |
| US8299077B2 (en) * | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| AU2010341229A1 (en) | 2009-12-17 | 2012-08-02 | Merck Patent Gmbh | Sphingosine kinase inhibitors |
| SG185617A1 (en) | 2010-05-31 | 2012-12-28 | Ono Pharmaceutical Co | Purinone derivative |
| US8859768B2 (en) | 2010-08-11 | 2014-10-14 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| CN103582637B (zh) | 2011-05-17 | 2015-08-12 | 弗·哈夫曼-拉罗切有限公司 | 酪氨酸激酶抑制剂 |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| US9458162B2 (en) | 2012-01-31 | 2016-10-04 | Nanjing Allgen Pharma Co. Ltd. | Cyclic molecules as bruton's tyrosine kinase inhibitors |
| JP6182593B2 (ja) * | 2012-04-20 | 2017-08-16 | アドヴィーナス セラピューティクス リミテッド | 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途 |
| WO2014025976A1 (en) | 2012-08-10 | 2014-02-13 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
| RU2015111133A (ru) * | 2012-09-13 | 2016-11-10 | Ф. Хоффманн-Ля Рош Аг | Ингибиторы тирозинкиназы брутона |
| KR101668574B1 (ko) | 2012-11-02 | 2016-10-24 | 화이자 인코포레이티드 | 브루톤 티로신 키나제 억제제 |
| CN103848810A (zh) | 2012-11-30 | 2014-06-11 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
| CA2922939A1 (en) * | 2013-09-03 | 2015-03-12 | Carna Biosciences, Inc. | Novel 2,6-diaminopyrimidine derivative |
| JP2016535764A (ja) * | 2013-10-04 | 2016-11-17 | ビヨンド オンコロジー ファーマシューティカル エルエルシー | ブルトンのチロシンキナーゼの阻害剤 |
| WO2015116485A1 (en) | 2014-01-29 | 2015-08-06 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as btk inhibitors |
| ES2897910T3 (es) | 2015-12-16 | 2022-03-03 | Boehringer Ingelheim Int | Derivados bipirazolilo útiles para el tratamiento de enfermedades autoinmunitarias |
-
2017
- 2017-01-12 US US16/069,046 patent/US10570118B2/en active Active
- 2017-01-12 WO PCT/US2017/013100 patent/WO2017123695A1/en not_active Ceased
- 2017-01-12 EP EP17701778.7A patent/EP3402789B1/en active Active
- 2017-01-12 JP JP2018536252A patent/JP6916185B2/ja active Active